U.S. Markets open in 7 hrs 15 mins
  • S&P Futures

    3,301.25
    +37.75 (+1.16%)
     
  • Dow Futures

    26,708.00
    +299.00 (+1.13%)
     
  • Nasdaq Futures

    11,259.25
    +126.50 (+1.14%)
     
  • Russell 2000 Futures

    1,555.40
    +16.20 (+1.05%)
     
  • Crude Oil

    37.46
    +0.07 (+0.19%)
     
  • Gold

    1,883.50
    +4.30 (+0.23%)
     
  • Silver

    23.52
    +0.16 (+0.69%)
     
  • EUR/USD

    1.1756
    +0.0007 (+0.0588%)
     
  • 10-Yr Bond

    0.7810
    0.0000 (0.00%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.3018
    +0.0031 (+0.2395%)
     
  • USD/JPY

    104.3690
    +0.0680 (+0.0652%)
     
  • BTC-USD

    13,258.14
    +16.19 (+0.12%)
     
  • CMC Crypto 200

    262.44
    -10.25 (-3.76%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,327.44
    -91.07 (-0.39%)
     

P/E Ratio Overview: Eli Lilly

Benzinga Insights
·2 mins read

 

In the current market session, Eli Lilly Inc. (NYSE: LLY) is trading at $150.32, after a 0.6% decrease. However, over the past month, the stock went up by 0.36%, and in the past year, by 34.86%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 11.96%.

The P/E ratio is used by long-term shareholders to assess the company’s market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.

View more earnings on LLY

Most often, an industry will prevail in a particular phase of a business cycle, than other industries.

Eli Lilly Inc. has a better P/E ratio of 24.66 than the aggregate P/E ratio of 18.09 of the Drug Manufacturers—General industry. Ideally, one might believe that Eli Lilly Inc. might perform better in the future than it’s industry group, but it’s probable that the stock is overvalued.

P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.